Decorin Protein Core Affects the Global Gene Expression Profile of the Tumor Microenvironment in a Triple-Negative Orthotopic Breast Carcinoma Xenograft Model

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Buraschi, Simone ^a   Neill, Thomas ^a   Owens, Rick T ^b   Iniguez, Leonardo A ^c   Purkins, George ^a   Vadigepalli, Rajanikanth ^a   Evans, Barry ^a   Schaefer, Liliana ^d   Peiper, Stephen C ^a   Wang, Zi Xuan ^a   Iozzo, Renato V ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b LIFECELL CORPORATION   (United States)

^c Roche NimbleGen Inc   (United States)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DECORIN; MESSENGER RNA; RECOMBINANT DECORIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BMP2K GENE; BRD4 GENE; CADM1 GENE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE REPRESSION; GUCY1A3 GENE; HEY1 GENE; HUMAN; HUMAN CELL; IL1B GENE; IMMUNOMODULATION; IN VIVO STUDY; IRG1 GENE; LIGP GENE; MICROARRAY ANALYSIS; MOUSE; MRGPRA2 GENE; NONHUMAN; PEG3 GENE; SCORING SYSTEM; SIGLECH GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ZC3HAV1 GENE;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CLUSTER ANALYSIS; COCULTURE TECHNIQUES; DECORIN; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; STROMAL CELLS; TRANSCRIPTOME; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEINS;

HOMO SAPIENS; MUS MUSCULUS;

EID: 84866551287     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045559     Document Type: Article

References (114)

1. Theocharis AD, Tzanakakis G, Karamanos NK, (2010) Proteoglycans in health and disease: Novel proteoglycan roles in malignancy and their pharmacological targeting. FEBS J 277: 3904-3923.
2. Edwards IJ, (2012) Proteoglycans in prostate cancer. Nat Rev Urology 9: 196-206.
3. Danielson KG, Fazzio A, Cohen I, Cannizzaro LA, Eichstetter I, et al. (1993) The human decorin gene: intron-exon organization, discovery of two alternatively spliced exons in the 5' untranslated region, and mapping of the gene to chromosome 12q23. Genomics 15: 146-160.
4. Santra M, Danielson KG, Iozzo RV, (1994) Structural and functional characterization of the human decorin gene promoter. A homopurine-homopyrimidine S1 nuclease-sensitive region is involved in transcriptional control. J Biol Chem 269: 579-587.
5. Mauviel A, Korang K, Santra M, Tewari D, Uitto J, et al. (1996) Identification of a bimodal regulatory element encompassing a canonical AP-1 binding site in the proximal promoter region of the human decorin gene. J Biol Chem 271: 24824-24829.
6. Adany R, Iozzo RV, (1990) Altered methylation of versican proteoglycan gene in human colon carcinoma. Biochem Biophys Res Commun 171: 1402-1413.
7. Adany R, Iozzo RV, (1991) Hypomethylation of the decorin proteoglycan gene in human colon cancer. Biochem J 276: 301-306.
8. Coppock DL, Kopman C, Scandalis S, Gilleran S, (1993) Preferential gene expression in quiescent human lung fibroblasts. Cell Growth & Differ 4: 483-493.
9. Mauviel A, Santra M, Chen YQ, Uitto J, Iozzo RV, (1995) Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-α. J Biol Chem 270: 11692-11700.
10. Kähäri V-M, Larjava H, Uitto J, (1991) Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-β-1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down- regulates decorin (PGII) mRNA levels in human fiborblasts in culture. J Biol Chem 266: 10608-10615.
11. Kolettas E, Rosenberger RF, (1998) Suppression of decorin expression and partial induction of anchorage-independent growth by the v-src oncogene in human fibroblasts. Eur J Biochem 254: 266-274.
12. Iozzo RV, (1988) Proteoglycans and neoplasia. Cancer Metastasis Rev 7: 39-50.
13. Iozzo RV, (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67: 609-652.
14. Iozzo RV, (1999) The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 274: 18843-18846.
15. Keene DR, San Antonio JD, Mayne R, McQuillan DJ, Sarris G, et al. (2000) Decorin binds near the C terminus of type I collagen. J Biol Chem 275: 21801-21804.
16. Häkkinen L, Strassburger S, Kahari VM, Scott PG, Eichstetter I, et al. (2000) A role for decorin in the structural organization of periodontal ligament. Lab Invest 80: 1869-1880.
17. Goldoni S, Owens RT, McQuillan DJ, Shriver Z, Sasisekharan R, et al. (2004) Biologically active decorin is a monomer in solution. J Biol Chem 279: 6606-6612.
18. Schaefer L, Iozzo RV, (2008) Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 283: 21305-21309.
19. Zhang G, Ezura Y, Chervoneva I, Robinson PS, Beason DP, et al. (2006) Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 98: 1436-1449.
20. Robinson PS, Lin TW, Jawad AF, Iozzo RV, Soslowsky LJ, (2004) Investigating tendon fascicle structure-function relationship in a transgenic age mouse model using multiple regression models. Ann Biomed Eng 32: 924-931.
21. Robinson PS, Huang TF, Kazam E, Iozzo RV, Birk DE, et al. (2005) Influence of decorin and biglycan on mechanical properties of multiple tendons in knockout mice. J Biomechanical Eng 127: 181-185.
22. Iozzo RV, Goldoni S, Berendsen A, Young MF (2011) Small leucine-rich proteoglycans. In: Mecham RP, editors. Extracellular Matrix: An overview. Springer. 197-231.
23. Kalamajski S, Oldberd Å, (2010) The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol 29: 248-253.
24. Hildebrand A, Romaris M, Rasmussen LM, Heinegård D, Twardzik DR, et al. (1994) Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem J 302: 527-534.
25. Ferdous Z, Wei VM, Iozzo RV, Höök M, Grande-Allen KJ, (2007) Decorin-transforming growth factor-β interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem 282: 35887-35898.
26. Baghy K, Dezsó K, László V, Fullár A, Péterfia B, et al. (2011) Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest 91: 439-451.
27. Baghy K, Iozzo RV, Kovalszky I, (2012) Decorin-TGFβ axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 60: 262-268.
28. Brown EL, Wooten RM, Johnson BJ, Iozzo RV, Smith A, et al. (2001) Resistance to Lyme disease in decorin-deficient mice. J Clin Invest 107: 845-852.
29. Liang FT, Wang T, Brown EL, Iozzo RV, Fikrig E, (2004) Protective niche for Borrelia burgdorferi to evade humoral immunity. Am J Pathol 165: 977-985.
30. Iozzo RV, Schaefer L, (2010) Proteoglycans in health and disease: Novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277: 3864-3875.
31. Zhu J-X, Goldoni S, Bix G, Owens RA, McQuillan D, et al. (2005) Decorin evokes protracted internalization and degradation of the EGF receptor via caveolar endocytosis. J Biol Chem 280: 32468-32479.
32. Reed CC, Gauldie J, Iozzo RV, (2002) Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21: 3688-3695.
33. Csordás G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, et al. (2000) Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275: 32879-32887.
34. Santra M, Eichstetter I, Iozzo RV, (2000) An anti-oncogenic role for decorin: downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 275: 35153-35161.
35. Schönherr E, Sunderkötter C, Iozzo RV, Schaefer L, (2005) Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 280: 15767-15772.
36. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, et al. (2007) Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-1 receptor and mammalian target of rapamycin. Am J Pathol 170: 301-315.
37. Merline R, Lazaroski S, Babelova A, Tsalastra-Greul W, Pfeilschifter J, et al. (2009) Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol 60 (suppl 4): 5-13.
38. Iozzo RV, Buraschi S, Genua M, Xu S-Q, Solomides CC, et al. (2011) Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 286: 34712-34721.
39. Goldoni S, Humphries A, Nyström A, Sattar S, Owens RT, et al. (2009) Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185: 743-754.
40. Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, et al. (2010) Decorin antagonizes Met receptor activity and downregulates β-catenin and Myc levels. J Biol Chem 285: 42075-42085.
41. Schaefer L, Iozzo RV, (2012) Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev 22: 56-57.
42. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, et al. (2006) Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281: 26408-26418.
43. Patel S, Santra M, McQuillan DJ, Iozzo RV, Thomas AP, (1998) Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 cells. J Biol Chem 273: 3121-3124.
44. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV, (1996) Decorin-induced growth suppression is associated with upregulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271: 18961-18965.
45. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, et al. (1997) Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100: 149-157.
46. Moore D, Kohn AD, De Ferrari GV, Kaykas A, (2004) Wnt and β-catenin signaling: Diseases and therapies. Nat Rev Genet 5: 689-699.
47. Albihn A, Johnsen JI, Henriksson MA, (2010) MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107: 163-224.
48. Jung P, Menssen A, Mayr D, Hermeking H, (2008) AP4 encodes a c-Myc-inducible repressor of p21. Proc Natl Acad Sci USA 105: 15046-15051.
49. Neill T, Schaefer L, Iozzo RV, (2012) Decorin, a guardian from the matrix. Am J Pathol 181: 380-387.
50. Bi X, Tong C, Dokendorff A, Banroft L, Gallagher L, et al. (2008) Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 29: 1435-1440.
51. Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, et al. (1999) Cooperative action of germline mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA 96: 3092-3097.
52. Schönherr E, Sunderkotter C, Schaefer L, Thanos S, Grässel S, et al. (2004) Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J Vasc Res 41: 499-508.
53. Järveläinen H, Puolakkainen P, Pakkanen S, Brown EL, Höök M, et al. (2006) A role for decorin in cutaneous wound healing and angiogenesis. Wound Rep Reg 14: 443-452.
54. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, et al. (2002) Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21: 4765-4777.
55. Neill T, Painter H, Buraschi S, Owens RT, Lisanti MP, et al. (2012) Decorin antagonizes the angiogenic network. Concurrent inhibition of Met, hypoxia inducible factor-1α and vascular endothelial growth factor A and induction of thrombospondin-1 and TIMP3. J Biol Chem 287: 5492-5506.
56. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RA, et al. (2005) Decorin prevents metastatic spreading of breast cancer. Oncogene 24: 1104-1110.
57. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, et al. (2008) An anti-metastatic role for decorin in breast cancer. Am J Pathol 173: 844-855.
58. Ständer M, Naumann U, Dumitrescu L, Heneka M, Löschmann P, et al. (1998) Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo. Gene Therapy 5: 1187-1194.
59. Tralhão JG, Schaefer L, Micegova M, Evaristo C, Schönherr E, et al. (2003) In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J 17: 464-466.
60. Biglari A, Bataille D, Naumann U, Weller M, Zirger J, et al. (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Therapy 11: 721-732.
61. Araki K, Wakabayashi H, Shintani K, Morikawa J, Matsumine A, et al. (2009) Decorin suppresses bone metastasis in a breast cancer cell line. Oncology 77: 92-99.
62. Hu Y, Sun H, Owens RT, Wu J, Chen YQ, et al. (2009) Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11: 1042-1053.
63. Leygue E, Snell L, Dotzlaw H, Troup S, Hiller-Hitchcock T, et al. (2000) Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol 192: 313-320.
64. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, et al. (2003) Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 9: 207-214.
65. Biaoxue R, Xiguang C, Hua L, Hui M, Shuanying Y, et al. (2011) Decreased expression of decorin and p57 (KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int J Biol Markers 26: 9-21.
66. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH, (2003) Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 5: R129-R135.
67. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, et al. (2008) Collagen density promotes mammary tumor initiation and progression. BMC Medicine 6: 11.
68. Maller O, Martinson H, Schedin P, (2010) Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia 15: 301-318.
69. Howell A, Landberg G, Bergh J (2009) Breast tumor stroma is a prognostic indicator and a target for therapy. Breast Cancer Res (Suppl 3): S16.
70. Schedin P, O'Brien J, Rudolph M, Stein T, Borges V, (2007) Microenvironment of the involuting mammary gland mediates mammary cancer progression. J Mammary Gland Biol Neoplasia 12: 71-82.
71. Iozzo RV, Cohen I, (1993) Altered proteoglycan gene expression and the tumor stroma. Cell Mol Life Sci 49: 447-455.
72. Iozzo RV, (1995) Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab Invest 73: 157-160.
73. Goldoni S, Iozzo RV, (2008) Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123: 2473-2479.
74. Huang DW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Prot 4: 44-57.
75. Chen B, Zhang D, Pollard JW, (2003) Progesterone regulation of the mammalian ortholog of methylcitrate dehydratase (Immune Response Gene 1) in uterine epithelium during implantation through the protein kinase C pathway. Mol Endocrinol 17: 2340-2354.
76. Lee CGL, Jenkins NA, Gilbert DJ, Copeland NG, O'Briend WE, (1995) Cloning and analysis of gene regulation of a novel LPS-inducible cDNA. Immunogenetics 41: 263-270.
77. Degrandi D, Hoffmann R, Beuter-Gunia C, Pfeffer K, (2009) The proinflammatory cytokine-induced IRG1 protein associates with mitochondria. J Interferon Cytokine Res 29: 55-67.
78. von Gunten S, Bochner BS, (2008) Basic and clinical immunology of Siglecs. Ann N Y Acad Sci 1143: 61-68.
79. Zerrahn J, Schaible UE, Brinkmann V, Guhlich U, Kaufman SHE, (2002) The IFN-Inducible Golgi- and endoplasmic reticulum-associated 47-kDa GTPase IIGP is transiently expressed during listeriosis. J Immunol 168: 3428-3436.
80. Sugerman PB, Faber SB, Willis LM, Petrovic A, Murphy GF, et al. (2004) Kinetics of gene expression in murine cutaneous graft-versus-host disease. Am J Pathol 164: 2189-2202.
81. Dharajiya N, Vaidya S, Sinha M, Luxon B, Boldogh I, et al. (2009) Allergen challange induces Ifng dependent GTPases in the lungs as part of Th1 transcriptome response in a murine model of allergic asthma. PLoS ONE 4: e8172.
82. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ, (2011) Natural innate and adaptive immunity to cancer. Ann Rev Immunol 29: 235-271.
83. Marchica CL, Pinelli V, Borges M, Zummer J, Narayanan V, et al. (2011) A role for decorin in a murine model of allergen-induced asthma. Am J Physiol Lung Cell Mol Physiol 300: 863-873.
84. Seidler DG, Mohamed NA, Bocian C, Stadtmann A, Hermann S, et al. (2011) The role for decorin in delayed-type hypersensitivity. J Immunol 187: 6108-6199.
85. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, et al. (2011) Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci Signal 4: ra75.
86. Liang Q-L, Chen G-Q, Li Z-Y, Wang B-R, (2011) Function and histopathology of a cell adhesion molecule TSLC1 in cancer. Cancer Invest 29: 107-112.
87. Heller G, Geradts J, Ziegler B, Newsham I, Filipitis M, et al. (2007) Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat 103: 283-291.
88. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, et al. (2008) Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112: 1489-1502.
89. Maegawa S, Yoshioka H, Itaba N, Kubota N, Nishihara S, et al. (2001) Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol Carcinogenesis 31: 1-9.
90. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101: 9309-9314.
91. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumor stroma promote breast cancer metastasis. Nature 449: 557-565.
92. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, et al. (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132.
93. Bissell MJ, Radisky D, (2001) Putting tumors in context. Nat Rev Cancer 1: 46-54.
94. Rønnov-Jessen L, Bissell MJ, (2009) Breast cancer by proxy: can the microenvironment be both the cause and consequence? Trends Mol Med 15: 5-13.
95. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
96. Nikitovic D, Berdiaki K, Chalkiadaki G, Karamanos N, Tzanakakis G, (2008) The role of SLRP-Proteoglycans in osteosarcoma pathogenesis. Connective Tissue Res 49: 235-238.
97. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6: 17-32.
98. Iozzo RV, Sanderson RD, (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15: 1013-1031.
99. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527.
100. Ma X-J, Salunga R, Tuggle JT, Gaudet J, Enright E, et al. (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100: 5974-5979.
101. Ma X-J, Dahiya S, Richardson E, Erlander M, Sgroi DC, (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11: R7.
102. Jiang X, Yu Y, Yang HW, Agar NYR, Frado L, et al. (2010) The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth. J Biol Chem 285: 8472-8480.
103. Deng Y, Wu X, (2000) Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci USA 97: 12050-12055.
104. Kearns AE, Donohue MM, Sanyal B, Demay MB, (2001) Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro. J Biol Chem 276: 42213-42218.
105. Tamimi Y, Lines M, Coca-Prados M, Walter MA, (2004) Identification of target genes regulated by FOXC1 using nickel agarose-based chromatin enrichment. Invest Ophthalmol Vis Sci 45: 3904-3913.
106. Liu H-P, Lin Y-J, Lin W-YWL, Sheu JJ-C, Lin H-J, et al. (2009) A novel genetic variant of BMP2K contributes to high myopia. J Clin Lab Anal 23: 362-367.
107. Gao G, Guo X, Goff SP, (2002) Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science 297: 1703-1706.
108. Zhu Y, Chen G, Lv F, Wang X, Ji X, et al. (2011) Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation. Proc Natl Acad Sci USA 108: 15834-15839.
109. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, et al. (2011) Endogenous Myc maintains the tumor microenvironment. Genes Dev 25: 907-916.
110. Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin N-E, et al. (2005) Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 85: 512-521.
111. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, et al. (2010) HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells. Autophagy drives compartment-specific oncogenesis. Cell Cycle 9: 3534-3551.
112. Ramamurthy P, Hocking AM, McQuillan DJ, (1996) Recombinant decorin glycoforms. Purification and structure. J Biol Chem 271: 19578-19584.
113. Cohen IR, Murdoch AD, Naso MF, Marchetti D, Berd D, et al. (1994) Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res 54: 5771-5774.
114. Ryynänen M, Ryynänen J, Solberg S, Iozzo RV, Knowlton RG, et al. (1992) Genetic linkage of Type VII collagen (COL7A1) to dominant dystrophic epidermolysis bullosa in families with abnormal anchoring fibrils. J Clin Invest 89: 974-980.